Showing results (61-70 of 133) with videos related to

Sort By:
Pageof 14
Cold Spring Harbor Molecular Case Studies|October 8, 2020
Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair-deficient tumorsNobuyuki Takahashi, Vinodh N Rajapakse, Lorinc Pongor, et al.
The Oncologist|June 9, 2020
A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast CancerMargaret E Gatti-Mays, Fatima H Karzai, Sanaz N Soltani, et al.
The Journal of Biological Chemistry|December 18, 2001
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cellsSeok Hee Park, Sae Ra Lee, Byung Chul Kim, et al.
Cancer Research|April 17, 2008
DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylationLunching Sun, Lei Huang, Phuongmai Nguyen, et al.
Cancer Cell|January 29, 2013
Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethalityCarole Sourbier, Bradley T Scroggins, Ranjala Ratnayake, et al.
Molecular Cell|March 23, 2011
Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activityMehdi Mollapour, Shinji Tsutsumi, Andrew W Truman, et al.
Oncology Letters|September 14, 2019
Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8<sup>+</sup> T cells compared with women with BRCA wild-type disease during the early disease courseJung-Min Lee, Dana-Adriana Botesteanu, Yusuke Tomita, et al.
British Journal of Cancer|June 25, 2019
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancerDaniel Morgensztern, Michal Rose, Saiama N Waqar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic AdenocarcinomaChristine Alewine, Mehwish Ahmad, Cody J Peer, et al.
Oncogene|March 1, 2005
Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cellsFederico A Steiner, Julie A Hong, Maria R Fischette, et al.
Pageof 14